A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight (SURMOUNT-1)
The main purpose is to learn more about how tirzepatide affects body weight in participants with overweight and obesity.
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Patients must have body mass Index (BMI) 30 kilograms per square meter (kg/m²), or 27 kg/m² and previous diagnosis with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease
Patients must have history of at least one unsuccessful dietary effort to lose body weight
Participants Must Not:
Patients must not have Diabetes mellitus
Patients must not have change in body weight greater than 5 kg within 3 months prior to starting study
Patients must not have obesity induced by other endocrinologic disorders or monogenetic or syndromic forms of obesity
Patients must not have history of pancreatitis
Patients must not have family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
Patients must not have history of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder within the last 2 years
Patients must not have any lifetime history of a suicide attempt
Lilly Trial Alerts
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo